statistiche ricercatore

Nazione	#
FI - Finlandia	1.893
US - Stati Uniti d'America	733
SG - Singapore	199
IT - Italia	115
CN - Cina	105
BR - Brasile	71
VN - Vietnam	62
PL - Polonia	47
DE - Germania	42
TW - Taiwan	40
HK - Hong Kong	39
GB - Regno Unito	26
BD - Bangladesh	23
FR - Francia	17
JP - Giappone	15
RU - Federazione Russa	14
CA - Canada	13
ID - Indonesia	13
TR - Turchia	11
IN - India	10
UA - Ucraina	9
SE - Svezia	8
AT - Austria	6
BE - Belgio	6
CO - Colombia	6
MX - Messico	6
NL - Olanda	6
AR - Argentina	5
DK - Danimarca	5
EG - Egitto	5
ES - Italia	5
ZA - Sudafrica	5
ET - Etiopia	4
IQ - Iraq	4
VE - Venezuela	4
AL - Albania	3
EC - Ecuador	3
JO - Giordania	3
KE - Kenya	3
LT - Lituania	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CH - Svizzera	1
CR - Costa Rica	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EE - Estonia	1
GR - Grecia	1
HU - Ungheria	1
IS - Islanda	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LV - Lettonia	1
MA - Marocco	1
MU - Mauritius	1
PR - Porto Rico	1
SD - Sudan	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TT - Trinidad e Tobago	1
Totale	3.622

Nome	#
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study	2.089
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	328
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy	298
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes	204
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells	166
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study	161
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer	157
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer	130
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)	119
Totale	3.652

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	7	0	0	0	0	0	0	0	0	0	0	0	7
2021/2022	54	4	8	5	3	1	1	7	3	2	5	3	12
2022/2023	76	8	8	3	7	8	10	5	11	10	1	5	0
2023/2024	76	1	12	4	1	7	11	2	2	1	6	16	13
2024/2025	308	6	12	23	11	30	30	10	14	57	28	45	42
2025/2026	2.829	87	41	64	85	128	70	114	79	1.946	100	73	42
Totale													3.652

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara